154 related articles for article (PubMed ID: 1779879)
21. Effect of clavulanic acid on the activities of ten beta-lactam agents against members of the Bacteroides fragilis group.
Lamothe F; Auger F; Lacroix JM
Antimicrob Agents Chemother; 1984 May; 25(5):662-5. PubMed ID: 6732233
[TBL] [Abstract][Full Text] [Related]
22. [Detection of beta-lactamases in the Bacteroides fragilis group].
Martin C; Dubreuil L; Sedallian A; Romond C
Pathol Biol (Paris); 1990 May; 38(5):470-3. PubMed ID: 2367153
[TBL] [Abstract][Full Text] [Related]
23. [Comparison of the in vitro activity of amoxycillin + clavulanic acid and ampicillin + sulbactam combinations against 50 Haemophilus influenzae strains producing beta lactamase].
Moittie D; Simonet M; Veron M
Pathol Biol (Paris); 1989 May; 37(5):390-3. PubMed ID: 2789362
[TBL] [Abstract][Full Text] [Related]
24. Ampicillin-sulbactam and ticarcillin-clavulanic acid: a comparison of their in vitro activity and review of their clinical efficacy.
Itokazu GS; Danziger LH
Pharmacotherapy; 1991; 11(5):382-414. PubMed ID: 1745624
[TBL] [Abstract][Full Text] [Related]
25. [ESBL-positive strains of the Bacteroides fragilis group isolated from patients at the regional hospital center in Płock (Poland)].
Rokosz A; Pawłowska J; Sawicka-Grzelak A; Luczak M
Med Dosw Mikrobiol; 2004; 56(3):245-53. PubMed ID: 15773501
[TBL] [Abstract][Full Text] [Related]
26. Susceptibility to cefazedone and cefazolin and production of beta-lactamase in in Bacteroides fragilis and other species of Bacteroidaceae.
Werner H; Krasemann C; Ungerechts J
Arzneimittelforschung; 1979; 29(2a):388-92. PubMed ID: 314805
[No Abstract] [Full Text] [Related]
27. Role of Bacteroides bivius beta-lactamase in beta-lactam susceptibility.
Lacroix JM; Lamothe F; Malouin F
Antimicrob Agents Chemother; 1984 Nov; 26(5):694-8. PubMed ID: 6335019
[TBL] [Abstract][Full Text] [Related]
28. [In vitro comparison of the beta lactamase-inhibitory action of clavulanic acid and sulbactam in ampicillin-resistant enterobacteria].
Grimm H
Arzneimittelforschung; 1987 Oct; 37(10):1116-9. PubMed ID: 3501722
[TBL] [Abstract][Full Text] [Related]
29. Evolution of beta-lactamase inhibitors.
Jackson D
Pharmacotherapy; 1991; 11(2 ( Pt 2)):37S-39S. PubMed ID: 2041830
[TBL] [Abstract][Full Text] [Related]
30. Role of beta-lactamase inhibitors in enterobacterial isolates producing extended-spectrum beta-lactamases.
Bhattacharjee A; Sen MR; Prakash P; Anupurba S
J Antimicrob Chemother; 2008 Feb; 61(2):309-14. PubMed ID: 18174199
[TBL] [Abstract][Full Text] [Related]
31. Activity of cefoperazone and two beta-lactamase inhibitors, sulbactam and clavulanic acid, against Bacteroides spp. correlated with beta-lactamase production.
Crosby MA; Gump DW
Antimicrob Agents Chemother; 1982 Sep; 22(3):398-405. PubMed ID: 6291451
[TBL] [Abstract][Full Text] [Related]
32. Activity of cefazolin and two beta-lactamase inhibitors, clavulanic acid and sulbactam, against Bacteroides fragilis.
Fekete T; McGowen J; Cundy KR
Antimicrob Agents Chemother; 1987 Feb; 31(2):321-2. PubMed ID: 3032097
[TBL] [Abstract][Full Text] [Related]
33. Cephamycin inactivation due to enzymatic hydrolysis by beta-lactamase from Bacteroides fragilis.
Yotsuji A; Minami S; Kakizawa H; Yasuda T; Takai A; Saikawa I; Inoue M; Mitsuhashi S
Antimicrob Agents Chemother; 1985 Dec; 28(6):773-7. PubMed ID: 3878690
[TBL] [Abstract][Full Text] [Related]
34. Augmentation effect of clavulanic acid with penicillin, cephalothin and ticarcillin against Bacteroides fragilis.
Bansal MB; Chuah SK; Oryema-Lalobo M; Thadepalli H
Chemotherapy; 1985; 31(3):173-7. PubMed ID: 3996086
[TBL] [Abstract][Full Text] [Related]
35. [In vitro and in vivo antimicrobial activities of cefmetazole against Bacteroides fragilis].
Isono M; Kawashima K; Yamada N; Aoki M; Kobayashi T; Sawa K; Watanabe K; Ueno K
Jpn J Antibiot; 1982 Jul; 35(7):1667-72. PubMed ID: 6757469
[TBL] [Abstract][Full Text] [Related]
36. Susceptibilities of 394 Bacteroides fragilis, non-B. fragilis group Bacteroides species, and Fusobacterium species to newer antimicrobial agents.
Appelbaum PC; Spangler SK; Jacobs MR
Antimicrob Agents Chemother; 1991 Jun; 35(6):1214-8. PubMed ID: 1929264
[TBL] [Abstract][Full Text] [Related]
37. In-vitro susceptibility of the Bacteroides fragilis group to cefoperazone, ampicillin, ticarcillin and amoxycillin combined with beta-lactamase inhibitors.
Barry AL; Jones RN; Packer RR
J Antimicrob Chemother; 1986 Jan; 17(1):125-7. PubMed ID: 3005222
[No Abstract] [Full Text] [Related]
38. Studies with cefuroxime and cefoxitin.
Geddes AM; McGhie D; Ball AP; Gould I
Scand J Infect Dis Suppl; 1978; (13):78-81. PubMed ID: 308260
[TBL] [Abstract][Full Text] [Related]
39. Beta-lactamases of type culture strains of the Bacteroides fragilis group and of strains that hydrolyse cefoxitin, latamoxef and imipenem.
Eley A; Greenwood D
J Med Microbiol; 1986 Feb; 21(1):49-57. PubMed ID: 3485198
[TBL] [Abstract][Full Text] [Related]
40. Purification and characterization of an imipenem hydrolysing metallo-beta-lactamase from Bacteroides fragilis.
Hedberg M; Edlund C; Lindqvist L; Rylander M; Nord CE
J Antimicrob Chemother; 1992 Feb; 29(2):105-13. PubMed ID: 1506324
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
